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Leprosy is an ancient disease considered to be a ne-
glected tropical disease that remains endemic and is still 
a major public health problem in some tropical countries, 
where it has been internationally recognized as being 
linked to the underdevelopment conditions. It still per-
sists in nonendemic areas because of the great mobility 
of people around the world and the increasing rates of im-
migration from countries where leprosy is endemic (Ooi 
& Moschella 2001, Gill et al. 2005, Walker & Lockwood 
2006). The natural course of the disease covers a wide 
variety of clinical conditions with systemic involvement. 
In this paper, we review the findings obtained in studies 
of the pathological mechanisms of leprosy, including a 
survey of the literature and of our own work.
Leprosy is a chronic infectious disease caused by 
the intracellular pathogen Mycobacterium leprae, which 
presents a long period of incubation, providing an ex-
traordinary opportunity to investigate the human im-
mune regulation of infection, because it presents a spec-
trum of clinical manifestations that correlate with the 
immune response of the host against the pathogen (Rid-
ley & Jopling 1966). The disease affects the peripheral 
nerves, skin and multiple internal organs, with a conse-
quent difficulty in its clinical recognition. Thus, knowl-
edge about this disease is important for a differential and 
conclusive diagnosis.
Immunopathological mechanisms in leprosy - The 
spectrum of clinical manifestations is correlated with the 
level of cell mediated immunity (CMI). Tuberculoid lep-
rosy (TT) is at one pole of this spectrum, characterized 
by restricted growth of the pathogen and high CMI. At 
the opposite pole is lepromatous leprosy (LL), in which 
the CMI is strikingly absent, affecting minimally resis-
tant hosts with a predominantly humoral immune re-
sponse in a T helper (Th)2 pattern and a widespread dis-
semination of the bacilli. Between these two poles, there 
is the borderline group, which can be divided into three 
subgroups: borderline tuberculoid, borderline-borderline 
and borderline lepromatous (Arnoldi et al. 1990).
During the natural course of the disease, reactional 
episodes may occur, during treatment and even after 
treatment, involving two types of reactions. The rever-
sal reaction (RR) seems to be associated with a sud-
den increase in CMI against M. leprae antigens and is 
characterized by a predominantly type-1 cytokine pro-
file consisting of interleukin (IL)-1β, tumour necrosis 
factor-α (TNF-α), IL-2 and interferon-γ (IFN-γ), more 
frequent in borderline patients. The erythema nodosum 
leprosum (ENL) type of reaction, which occurs in multi-
bacillary (MB) leprosy patients (LPs), is a more systemic 
reaction than the RR and is also immunopathologically 
more complex (Naafs 1994). In this reaction, it has been 
shown that there is a selective increase in IL-6, IL-8 and 
IL-10 levels, whereas the levels of IL-4 and IL-5 remain 
unchanged (Yamamura et al. 1992)
Taking into account the clinical characteristics and 
the host’s immunological reactivity to the spectral mani-
festations of leprosy, we carried out investigations to un-
derstand whether the mediators could be related to these 
manifestations. First of all, we observed that there is a 
potent production of anti-phenolic glycolipid-I (PGL-I) 
antibody in LL, but not in TT, with the humoral re-
sponse, therefore, considered not to play a protective role 
(Callera et al. 1993). The serological levels of anti-PGL-I 
antibody can be reduced with multidrug therapy (MDT) 
(Zenha et al. 2009). We found that the anti-PGL-I anti-
body can be detected in saliva and serum and its deter-
mination may be useful for the evaluation of antigen ex-
posure and response to MDT and for distinguishing MB 
from paucibacillary (PB) patients (Bonfitto et al. 2009). 
Another application of the detection of this antibody was 
studied in the evaluation of household contacts (HHC) of 
LPs, where we observed that the serum anti-PGL-I IgM 
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antibody may be useful for evaluating antigen exposure 
and as a tool for an early leprosy diagnosis in HHC (Ba-
zan-Furini et al. 2011).
In addition, elevated TNF-α levels were detected 
in supernatant cultures of macrophages from TT pa-
tients compared to those from LL patients (Silva & Foss 
1989a), reflecting the impairment of macrophages from 
LL patients. We also observed that a glycolipid frac-
tion from M. leprae is able to induce an inflammatory 
response (Silva & Foss 1989b) and the PGL-I antigen 
can suppress the cytokine release of human monocytes, 
suggesting that the antigens from M. leprae could regu-
late the immunological response in leprosy (Silva et al. 
1993). Moreover, a correlation was observed between se-
rum TNF-α detection, increased plasma C-reactive pro-
tein (CRP) and in vitro suppression of the T lymphocyte 
response to a mitogen (Con-A) during ENL, indicating 
the serum CRP levels are a clinical parameter that can 
be used to evaluate the intensity of the inflammatory re-
sponse in ENL (Foss et al. 1993).
Despite the evidence of the inability of LL mac-
rophages to destroy the bacillus, the mechanisms in-
volved in regulating the activity of these cells have not 
been elucidated. Thus, we studied transforming growth 
factor-β1 (TGF-β1), a cytokine with macrophage-sup-
pressing activity present in diseases caused by intracel-
lular parasites (Silva et al. 1991, Barral-Neto et al. 1992, 
Bermudez et al. 1993, Lotz & Seth 1993). Initially, the 
detection of TGF-β1 in dermal lesions of different clini-
cal forms of leprosy was evaluated (Goulart et al. 1996) 
and marked immunohistochemical staining for TGF-β1 
was detected in macrophages from lesions of LL patients, 
which contained large amounts of bacilli, demonstrating 
that the inability of macrophages to process M. leprae 
was probably associated, at least in part, with the action 
of TGF-β1 inhibiting the microbicidal activity.
TGF-β1, a cytokine produced by activated mac-
rophages and other cells, is a potent pro-inflammatory 
and immunosuppressive molecule with a plethora of im-
munoregulatory effects which are described as bifunc-
tional (Wahl et al. 1989), in addition to effects on cell 
growth and differentiation (Wakefield et al. 1988). The 
immunosuppressive effect of TGF-β1 on leprosy lesions 
is more evident by the inhibition of the production of 
intermediate oxygen-reactive and nitrogen-reactive fac-
tors (Tsunawaki et al. 1988, Ding et al. 1990), leading to 
the progression of infection.
The role of circulating monocytes directed against 
M. leprae and its products and their relationship with the 
production of TGF-β1 by macrophages resident in this 
microenvironment was investigated in blood monocytes 
from patients with different clinical forms of leprosy 
and healthy individuals. TGF-β1 produced in vitro by 
cultures of adherent cells from peripheral blood mono-
nuclear cells (PBMC) was spontaneously released in 
all clinical forms of leprosy and in healthy individuals, 
but patients with ENL showed markedly higher TGF-β1 
concentrations than all other patients and controls. This 
led to the conclusion that TGF-β1 appears to play dif-
ferent roles in leprosy: it presents a pro-inflammatory 
effect on the inflammatory reaction, especially in ENL, 
stimulating the Th2 response and an immunosuppres-
sive effect in the presence of PGL-I or other M. leprae 
antigens (Goulart et al. 2000).
Although the immunological aspects of leprosy have 
been extensively investigated, the exact mechanism of 
the systemic involvement of the disease remains unclear 
(Britton & Lockwood 2004). Leprosy is a pleiotropic dis-
ease that can resemble many dermatologic and neurologi-
cal diseases and affects multiple organs, making its rec-
ognition challenging. In particular, the neurological and 
endocrine manifestations caused by leprosy have been 
long recognized but underestimated, even by specialists.
Endocrine axis in leprosy - The pathogenic correla-
tion between the patterns of inflammation in the poles of 
the leprosy spectrum and the hormonal disarrangements 
has been investigated. The action of the hypothalamic-
pituitary-adrenal axis on the involvement of the adrenal 
glands has been recorded in about 30% of leprosy cases 
in autopsy series (Powell & Swan 1955, Desikan & Job 
1968, Bernard & Vazquez 1973), in which granulomas 
bacilli and amyloidal infiltration were documented in 
the adrenal cortex of LL cases.
The evaluation of cortisol and adrenal androgen 
secretion in a series of untreated PB and MB patients 
without clinically manifested adrenocortical hypofunc-
tion at baseline showed that corticotrophin-releasing 
hormone-stimulated adrenocorticotropic hormone and 
cortisol secretion did not differ from control. However, 
the levels of the adrenal androgen dehydroepiandroster-
one sulphate (DHEA-S) were significantly lower in LPs 
compared to sex-matched control subjects. Additionally, 
a significant inverse correlation of both IL-6 and TNF-α 
with plasma DHEA-S levels was observed, suggesting 
the influence of inflammatory cytokines on adrenal an-
drogen secretion in leprosy (Leal et al. 2003). This study 
was the first to investigate the relationship between ad-
renal hormones and inflammatory cytokine patterns in 
leprosy. A link between DHEA-S and the pathogenesis 
of systemic inflammatory processes in humans has been 
poorly explored. 
The role played by local cortisol-cortisone metabo-
lism in the skin has been investigated in leprosy and 
it has been hypothesized that inflammatory cytokines 
could locally affect the concentration of cortisol in lep-
rosy skin lesions and the development of leprosy reac-
tions (Rook & Baker 1999, Andersson et al. 2007). This 
regulatory mechanism of effective cortisol concentration 
extended to other tissues such as the peripheral nervous 
system could be adjusted by the administration of exog-
enous cortisol in preventing the progression of neuropa-
thy (Jardim et al. 2007). 
The gonadal involvement in leprosy, restricted al-
most exclusively to the testis and its manifestations have 
long been recognized and addressed clinically and in 
histopathologic studies, semen analysis and hormonal 
assays (Baptista 1937). There is wide variability in the 
reported frequency of testicular involvement in leprosy, 
ranging from 8-80%. In random surveys, about 50% of 
the screened LL patients showed hormonal changes sug-
gestive of unsuspected gonadal involvement (Ree et al. 
1981, Levis et al. 1989). The occurrence of hypogonad-
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ism secondary to leprosy and its important consequenc-
es such as infertility and osteoporosis may be underesti-
mated by specialists in leprosy.
Studies of ovarian function assessment in female 
LPs are rare and in those in which histopathology was 
performed, the ovaries were not involved (Grabstald 
& Swan 1952, Bernard & Vazquez 1973). Neena et al. 
(2003) detected menstrual irregularity in 30% of women 
of reproductive age with MB leprosy, as well as signifi-
cantly high levels of luteinizing hormone (LH) and folli-
cle-stimulating hormone (FSH). 
The hormone profile of the male gonadal axis in lep-
rosy has been extensively studied, showing low basal 
levels of testosterone and high basal LH and FSH levels 
secondary to the loss of testosterone-induced negative 
feedback in 30-80% of LL patients investigated (Ree et 
al. 1981, Rea 1988, Levis et al. 1989, Saporta & Yuksel 
1994). The data regarding plasma prolactin levels in lep-
rosy are controversial (Rolston et al. 1981, Kannan & 
Vijaya 1984, Saporta & Yuksel 1994, Leal et al. 2006) 
and the high prolactin levels observed have been attrib-
uted to estrogen stimulation (Kannan & Vijaya 1984). 
High plasma estrogen levels were demonstrated in LL 
patients and were attributed to the peripheral conversion 
of androgens and to impaired hepatic metabolism (Shilo 
et al. 1981, Kannan & Vijaya 1984, Garg et al. 1989, Sa-
porta & Yuksel 1994).
The clinical manifestations of testicular damage 
in leprosy include gynecomastia, erectile dysfunction, 
infertility and changes in secondary sexual charac-
teristics (female distribution of body hair and reduced 
testicular volume). Gynecomastia is the most obvious 
clinical manifestation of hormone dysfunction in lep-
rosy, reported in up to 85% of LL cases (Baptista 1937, 
Grabstald & Swan 1952, Shilo et al. 1981, Abraham et 
al. 1990, Saporta & Yuksel 1994) and has been attrib-
uted to the hormonal imbalance between estrogen and 
testosterone (Leal & Foss 2009). 
In an investigation of the pituitary-gonadal hormones 
and the interleukin pattern in a series of random selected 
PB and MB LPs, LH and FSH were positively correlated 
with IL-1β, IL-6 and TNF-α and testosterone was in-
versely correlated with IL-6 and TNF-α, suggesting that 
these cytokines may have a direct effect at the testicular 
level and may be of pathogenic significance in leprosy 
(Leal et al. 2006). This favours the hypothesis that the 
inflammatory cytokines seem to play a fundamental role 
in the local control mechanisms of testosterone synthesis 
in Leydig cells and indicates the treatment of hypogo-
nadism in leprosy since testosterone therapy is associ-
ated with the improvement of clinical and inflammatory 
markers (Leal & Foss 2009). Additionally, Rodrigues 
et al. (2011) reported that inflammatory response to M. 
leprae is associated with alterations in the insulin-like 
growth factor-1 (IGF-1) signalling circulating IGF-1/IGF 
BP-3 levels as possible predictive biomarkers for ENL in 
LL patients at diagnosis.
Regarding calcium and bone metabolic disease, 
hypo and hypercalcaemia have been described in lep-
rosy (Hoffman & Korzeniowski 1986, Rao & Saha 1986, 
Ryzen et al. 1988, Couri et al. 2004). The most common 
metabolic bone disease, osteoporosis, is of particular 
interest in leprosy because of the risk of bone fracture 
in patients who already have neural lesions and both 
specific and nonspecific bone changes that result in de-
formities and disabilities (Paterson & Rad 1961, Thappa 
et al. 1992, Illarramendi et al. 2001). 
Hypercalcaemia and abnormal 1,25 dihydroxy vi-
tamin D, parathyroid hormone (PTH) and PTH-related 
protein concentrations have been reported in only a few 
patients with borderline and LL (Couri et al. 2004). On 
the other hand, hypercalcaemia was observed in two 
unusual cases of chronic granulomatous diseases pre-
senting normal levels of vitamin D in light of low lev-
els of PTH (Sharayyef et al. 2011). It was reported that 
bone mass loss is an early event in LPs and is frequently 
already present at diagnosis (Ribeiro et al. 2007). The 
development of bone metabolism alterations in leprosy 
have been investigated and it was observed that M. le- 
prae inhibits the expression of phosphate-regulating 
gene with homologies to endopeptidase on the X chro-
mosome in Schwann cells and osteoblasts, and that it can 
lead to extensive bone disease (Silva et al. 2010).
There are few data regarding endocrine dysfunction 
in leprosy, which is usually neglected, even by special-
ists. Nevertheless, this condition contributes to the bur-
den of the disease, especially the frequent involvement 
of the testis and secondary complications, such as infer-
tility and osteoporosis (Leal & Foss 2009). Besides the 
activity on bone metabolism, the involvement of vitamin 
D in the steps of intracellular antimicrobial mechanisms 
has been reported (Matzner et al. 2011) and most recent-
ly it was demonstrated that microRNA-21 targets the 
vitamin D-dependent antimicrobial pathway in leprosy 
(Liu et al. 2012).
Reactional episodes - Leprosy reactional episodes 
can be responsible for much of the permanent nerve 
damage, leading to disability and deformities, and there 
is evidence that these episodes may be associated with 
an infectious process. We investigated the role of coex-
isting factors in the patient’s condition that could be re-
lated to the exacerbation of M. leprae infection. First of 
all, we determined the frequency of leprosy reactional 
episodes and coinfections in LPs in order to evaluate 
whether there was a relationship between these condi-
tions. We found that ENL was the most prevalent reac-
tion type, especially in MB patients presenting any coin-
fection. Additionally, we verified that oral infections, 
including periodontal diseases and dental abscess, were 
the most prevalent coinfection, followed by urinary tract 
infection, sinusopathy and viral hepatitis (ACF Motta 
et al., unpublished observations). These findings sug-
gest that the presence of coinfections may be involved in 
the development and maintenance of leprosy reactional 
episodes. Thus, it is necessary to screen LPs for chronic 
systemic and local infections because treatment of coin-
fections may improve their care and help prevent disabil-
ity caused by leprosy reactions. 
Additionally, we evaluated the expression of pro-
inflammatory serum biomarkers in LPs presenting oral 
infections (periodontal diseases, irreversible pulpitis, 
pulpal necrosis, or inflammatory periapical lesions) and 
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we observed higher CRP, IL-10, IL-1 and IL-6 levels 
in the presence of oral infections, suggesting that oral 
infections can act as a maintenance factor of the pro-
inflammatory state (Motta et al. 2010, 2011). Thus, the 
coexistence of chronic oral infections with leprosy can 
stimulate the inflammatory reaction by elevating the ex-
pression of intracellular inflammatory markers.
Considering that the measurement of biomarkers in 
serum, saliva and plasma cannot show the real partici-
pation of peripheral blood cells and the amount of cy-
tokines produced by each cell population, impairing the 
understanding of the inflammatory response, we deter-
mined the intracellular profile of pro-inflammatory cy-
tokines such as IL-2, IL-4, IL-10 and IFN-γ in PBMCs 
from LPs stratified according to the presence of chronic 
oral infections (periodontal and/or dental infections) 
to determine whether these coinfections could be as-
sociated with pro-inflammatory activity in leprosy. We 
verified low percentages of CD3+ lymphocytes bearing 
IL-2, IL-10 and IFN-γ in LPs with oral infections and 
reduced percentages of IL-4 and IFN-γ in LPs without 
oral infections. However, LPs with and without oral in-
fection presented high percentages of CD3+ cells bearing 
IL-4 (unpublished observations). We concluded that the 
occurrence of oral infections favours the expression of 
intracellular cytokines and probably the inflammatory 
reaction, acting as a stimulatory signal triggering the re-
actional episodes in LPs. 
Based on these studies, where we evaluated the re-
lationship between leprosy reactions and coinfections, 
we can suggest that coinfection treatment may improve 
the care of LPs in order to prevent reactional episodes. 
These results may help for the treatment of LPs as a tool 
for public health professionals, especially physicians, for 
the follow-up and treatment of leprosy.
Neurological abnormalities in leprosy - In addition 
to the systemic involvement consequent to the develop-
ment of the infectious process induced by M. leprae, 
neurological abnormalities have been investigated in 
LPs. Initially the best technical approach to the detec-
tion of peripheral nerve involvement in leprosy neuropa-
thy was extensively investigated. It was observed that 
the sensory action potentials are better evaluated by 
the near-nerve potential technique that records poten-
tials from nerve fibres as small as 4-6 RM in diameter 
(Marques et al. 2003).
This result show that electrophysiology (EPG) is a 
sensitive resource for the detection of the early stages of 
peripheral nerve involvement in leprosy, even regarding 
the initial forms of the diseases, registering the earliest 
alterations of sensory fibres. However, EPG is an inva-
sive procedure and the implementation of electroneu-
romyography for the diagnosis of nerve involvement is 
limited, because it requires a high ability on the part of 
the neurologist, facts that limit the application of these 
procedures to an endemic disease such as leprosy. Thus, 
considering the limitation of the EPG, a new noninva-
sive technique was sought to detect peripheral nerve ab-
normalities in LPs. The option was to apply ultrasound 
to evaluate the peripheral nerves in leprosy.
We initially investigated the potential of ultrasound 
to detect neurological abnormalities in patients with the 
polar forms of leprosy looking for the role of ulnar nerve 
sonography in leprosy neuropathy with electrophysi-
ologic correlation; we observed that nerve sonography 
and EPG were complementary for identifying ulnar 
nerve neuropathy in patients with leprosy with clinical 
symptoms. This reinforces the role of sonography in the 
investigation of leprosy ulnar neuropathy (Elias Junior 
et al. 2009). The ulnar nerve was chosen because it is the 
most commonly affected nerve in leprosy and is easily 
accessible for clinical evaluation.
We are currently investigating the cross-sectional 
area of peripheral nerves in patients presenting the spec-
trum of clinical manifestations of leprosy and have ob-
served that the ratio between the cross-sectional area of 
the pre-tunnel and the tunnel of the ulnar nerve can be 
helpful in the diagnosis of neuropathy caused by M. le- 
prae (unpublished observations). 
On the other hand, we also observed that patients with 
neuritis related to reactional episodes have been treated 
with corticotherapy for long time and this therapy causes 
an immunosuppressive state favouring the manifestation 
of opportunistic infections (Wambier et al. 2011).
Taken as a whole, these findings could contribute to 
the understanding and control of these conditions and 
should help improve patient care and thus prevent the on-
set of physical impairment and the stigma of the disease.
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